NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Jan Sloves Applaudes Gregory Piazza and Colleagues: Excellent Review Paper on SVT
Jan Sloves;Gregory Piazza/LinkedIn
Sep 25, 2025, 17:14

Jan Sloves Applaudes Gregory Piazza and Colleagues: Excellent Review Paper on SVT

Jan Sloves, President and Consultant at Vascular Imaging Professionals LLC, shared on LinkedIn:

”My Top 6 Teaching Points from the JAMA 2025 Review on Superficial Vein Thrombosis by Gregory Piazza and colleagues.

Excellent Review Paper, Congratulations to the Authors

1. Clinical Relevance and Risk of VTE
SVT has a meaningful risk of progression to deep vein thrombosis (DVT) or pulmonary embolism (PE), especially if untreated, up to 10% of patients develop DVT or PE. Approximately 25% present with concomitant DVT, and thromboembolic events can occur in up to 7% within 90 days of SVT diagnosis

2. Diagnosis: Clinical and Imaging Approach
SVT typically presents with a tender, palpable cord and erythema along a superficial vein. While history and physical are often sufficient, duplex US should be performed if there is diagnostic uncertainty, concern for extension, or major risk factors. D-dimer is not sensitive enough to reliably exclude SVT

3. Risk Stratification
Key risk factors for SVT include varicose veins, pregnancy, cancer, indwelling catheters (for upper extremity SVT), immobilization, obesity, and history of VTE. Prognosis is worse for patients with cancer, male sex, absence of varicose veins, or involvement of the saphenofemoral/popliteal junction

4. Indications for Anticoagulation
Anticoagulation is strongly recommended for:
• SVT ≥ 5 cm in length,
• SVT with symptoms refractory to conservative therapy,
• SVT within 3 cm of a deep vein (should be treated as DVT with therapeutic anticoagulation).
 First-line therapy is fondaparinux 2.5 mg daily for 45 days; alternatives include rivaroxaban 10 mg daily or enoxaparin 40 mg daily

5. Conservative Measures and Other Therapies
Elastic compression stockings and NSAIDs offer symptomatic relief and are appropriate in select low-risk cases. Topical therapies (such as heparin ointment) may add symptom benefits, but surgical/ablative intervention is not routinely advised unless significant venous reflux is confirmed

6. Follow-Up and Outcomes
Patients should be counseled to seek further evaluation if symptoms worsen or fail to improve within 7 days. Early follow-up duplex US is advised for proximal progression or new symptoms. Residual reflux is common after SVT and may lead to chronic venous insufficiency, but evidence for reducing post-SVT ulceration is still lacking.

Subscribe to the only newsletter built for vascular pros”

Read the full article in JAMA.

Article: Superficial Vein Thrombosis. A Review

Authors: Gregory Piazza, Darsiya Krishnathasan, Nada Hamade, Francisco Ujueta, Giovanni Scimeca, Marcos Ortiz-Rios, Bridget McGonagle, Jean-Philippe Galanaud, David Jiménez, Manuel Monreal, John Fanikos, Anahita Dua, Leben Tefera, Raghu Kolluri, Sahil Parikh, Walter Ageno, Samuel Goldhaber, Jeffrey Weitz, Lisa Moores, Isabelle Quéré, Behnood Bikdeli

Jan Sloves Applaudes Gregory Piazza and Colleagues: Excellent Review Paper on SVT

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.

Anahita Dua Behnood Bikdeli Bridget McGonagle Darsiya Krishnathasan David Jimenez duplex US DVT Francisco Ujueta Giovanni Scimeca Gregory Piazza Health Hematology Hemostasis Hemostasis Today Isabelle Quéré JAMA 2025 Jan Sloves Jean-Philippe Galanaud Jeffrey Weitz John Fanikos Leben Tefera Lisa Moores Manuel Monreal Marcos Ortiz-Rios Medicine Nada Hamade NSAIDs PE Raghu Kolluri Sahil Parikh Samuel Goldhaber Superficial Vein Thrombosis SVT thrombosis VTE Walter Ageno
NewsFeed